Fig. 3.

Treatment of mice with orthotopic PancOVA tumors with DC vaccination and gemcitabine prolongs survival despite reduced numbers of tumor-reactive CD8⁺ T-cells. a PancOVA tumors were implanted orthotopically in the pancreas. Treatment with gemcitabine, unloaded DC (U-DC), OVA-DC or OVA-DC + gemcitabine was started on day 7. Treatment efficacy is blotted as Kaplan–Meier survival curves. Data are pooled from two independent experiments (total of n = 15 mice in the OVA-DC and/or gemcitabine groups). b, c Frequencies of SIINFEKL- and p15E-reactive CD8⁺ T-cells were determined by IFN-γ ICS 35 days after tumor inoculation. Data are representative of two independent experiments (n = 7 per group). *P < 0.05